CD274 and esophageal adenocarcinoma: Meanwhile, immunotherapy dataset GSE165252, which was originally about atezolizumab (a PD-L1 inhibitor) treating esophageal adenocarcinoma, was used as an external dataset to verified the signature’s ability of making immunotherapy response predictions.